Literature DB >> 16574997

Developing a new framework for dose calculation.

Howard Gurney.   

Abstract

Mesh：

Substances：

Year:  2006        PMID： 16574997     DOI： 10.1200/JCO.2005.05.1607

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

Review 1.  Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect.

Authors:  Guido Bocci; Robert S Kerbel
Journal:  Nat Rev Clin Oncol       Date:  2016-05-17       Impact factor: 66.675

2.  Chemotherapy dosing strategies in the obese, elderly, and thin patient: results of a nationwide survey.

Authors:  Kathryn M Field; Suzanne Kosmider; Michael Jefford; Michael Michael; Ross Jennens; Michael Green; Peter Gibbs
Journal:  J Oncol Pract       Date:  2008-05       Impact factor: 3.840

Review 3.  Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray".

Authors:  B Brans; L Bodei; F Giammarile; O Linden; M Luster; W J G Oyen; J Tennvall
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-05       Impact factor: 9.236

4.  Comparison of toxicity and effectiveness between fixed-dose and body surface area-based dose capecitabine.

Authors:  Femke M de Man; G D Marijn Veerman; Esther Oomen-de Hoop; Maarten J Deenen; Didier Meulendijks; Caroline M P W Mandigers; Marcel Soesan; Jan H M Schellens; Esther van Meerten; Teun van Gelder; Ron H J Mathijssen
Journal:  Ther Adv Med Oncol       Date:  2019-04-15       Impact factor: 8.168

5.  Intra-patient dose escalation in Ewing's sarcoma treated with vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide and etoposide: a retrospective review.

Authors:  Jeremy Lewin; Samantha Wieringa; Marnie Collins; Jayesh Desai; Lisa Orme; Senthil Lingaratnam; David M Thomas
Journal:  Clin Sarcoma Res       Date:  2013-12-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.